1. Introduction

Biopharmaceutical regulation in Australia is the legal and administrative framework governing the research, clinical development, manufacture, approval, marketing, distribution, monitoring and withdrawal of medicines produced through biological processes.

Unlike conventional small-molecule medicines, biopharmaceuticals may be manufactured using living cells, recombinant DNA technology, biological materials or complex biological processes. Their quality and safety can depend on cell lines, manufacturing conditions, purification methods, sterility and the consistency of the final product.

Examples include:

Monoclonal antibodies used to treat cancer and autoimmune diseases.

Recombinant proteins, including certain therapeutic hormones.

Vaccines and plasma-derived medicines.

Cell and gene therapies.

Biosimilars, which are highly similar to an already approved biological medicine.

Australia regulates these products principally through the Therapeutic Goods Administration (TGA), operating within the Australian Government's therapeutic-goods framework. Most medicines must be authorised and included in the Australian Register of Therapeutic Goods (ARTG) before lawful supply, subject to applicable exemptions and special access arrangements.

Therapeutic Goods Administration (TGA)+1

A crucial legal distinction: Australia does not classify every product derived from biological material as a biological under the same regulatory pathway. Many vaccines, recombinant medicines and plasma-derived products are regulated as biological medicines under the medicines framework, while certain human-cell and tissue products are regulated under the separate statutory category of biologicals. The correct classification determines the applicable approval requirements.

Therapeutic Goods Administration (TGA)+1

2. Principal legislation and regulatory institutions

Therapeutic Goods Act 1989 (Cth)

The principal Commonwealth statute. It establishes the regulatory framework for therapeutic goods, market authorisation, enforcement, recalls, information requirements and penalties. Its provisions governing medicines and biologicals are particularly important.

Federal Register of Legislation+1

Therapeutic Goods Regulations 1990

Provide detailed rules supporting the Act, including requirements relevant to applications, manufacturing, supply and advertising.

Therapeutic Goods Administration (TGA)

Evaluates products, administers the ARTG, oversees relevant manufacturing standards, monitors safety after approval and can take regulatory action where legal requirements are not met.

Department of Finance+1

Product-specific standards and regulatory guidance

Instruments such as applicable Therapeutic Goods Orders, manufacturing requirements and Australian Regulatory Guidelines for Biologicals provide additional rules for relevant product categories. Guidance explains the regulator's approach; binding obligations ultimately depend on legislation and applicable instruments.

Therapeutic Goods Administration (TGA)+1

Other institutions also play important roles. The Pharmaceutical Benefits Scheme (PBS) and the Pharmaceutical Benefits Advisory Committee (PBAC) are involved in decisions concerning public subsidy, while state and territory authorities regulate matters such as prescribing and aspects of healthcare delivery.

Market authorisation and public reimbursement are different decisions. TGA approval concerns whether a product meets the relevant regulatory requirements; PBS listing involves a separate assessment of whether public funding should be provided under the applicable scheme.

3. Classification of biopharmaceutical products

Classification is the first major legal question because different products may be subject to different statutory pathways.

The TGA's official guidance distinguishes biological medicines from products regulated under the statutory category of biologicals. It also identifies excluded products and products subject to different therapeutic-goods rules.

Therapeutic Goods Administration (TGA)+1

Why classification matters

Suppose a company develops a genetically engineered antibody to treat cancer. It cannot assume that the separate biologicals pathway automatically applies merely because the medicine originates from biological processes. The company must establish the product's legal classification and follow the relevant medicines approval requirements.

By contrast, a human-cell-based therapeutic product may be regulated as a biological under Part 3-2A of the Therapeutic Goods Act 1989, subject to statutory definitions, exclusions and applicable instruments.

Federal Register of Legislation+1

4. Pre-market approval and the ARTG

The ARTG is central to Australia's system of market authorisation. A sponsor seeking to supply a new biopharmaceutical generally must obtain the relevant authorisation and satisfy the applicable registration requirements.

Typical regulatory pathway

Product classification

Identify whether the product is a medicine, biological, medical device or another regulated category.

Preclinical development

Generate appropriate evidence on pharmacology, toxicology, product characteristics and potential risks.

Clinical-trial authorisation arrangements

Conduct human research under the applicable Australian clinical-trial framework, with ethics review and regulatory requirements.

Marketing application

Submit evidence on quality, safety, efficacy, manufacturing and proposed product information.

Regulatory evaluation

The TGA evaluates the application under the relevant pathway and may seek further information.

ARTG inclusion and supply

If approved, the product is included in the relevant ARTG entry, subject to applicable conditions.

Post-market monitoring

Continue safety reporting, quality oversight, recordkeeping and compliance with any imposed conditions.

The exact process, evidence requirements and timelines depend on the product category and application type. This sequence is a general illustration rather than a guarantee that every product follows an identical pathway.

Health, Disability & Ageing Dept.+1

Clinical trials

Clinical development must comply with the applicable Australian framework for clinical trials. Australia's Clinical Trial Notification (CTN) and Clinical Trial Approval (CTA) schemes are distinct mechanisms for commencing trials; neither is equivalent to marketing approval.

Under the CTN scheme, the relevant Human Research Ethics Committee (HREC) reviews the trial, and the sponsor notifies the TGA through the required process. Under the CTA scheme, the TGA undertakes the applicable regulatory assessment before the trial proceeds.

Ethical review, informed consent, appropriate safety oversight and compliance with relevant clinical-trial standards remain essential. Approval to conduct a trial does not establish that the product is safe and effective for general commercial supply.

Quality, safety and efficacy

A biopharmaceutical application must address three closely related questions:

Quality: Is the product consistently manufactured to appropriate standards, with adequate controls for identity, purity, potency, stability and contamination?

Safety: Are the known and potential risks adequately characterised and managed?

Efficacy: Is there sufficient evidence that the product delivers the claimed therapeutic benefit for its proposed use?

For complex biologics, manufacturing consistency is particularly important. Changes to a cell line, production process or purification method can affect the product and may require comparability evidence or regulatory approval, depending on the change and the applicable requirements.

5. Manufacturing, GMP and product standards

Manufacturing regulation is fundamental to biopharmaceutical law because the biological production process can influence the safety and performance of the final medicine.

Relevant obligations may include:

Compliance with applicable Good Manufacturing Practice (GMP) requirements.

Appropriate qualification and oversight of manufacturing facilities.

Validation of production and testing methods.

Control of contamination and adventitious agents.

Batch release, stability testing and quality documentation.

Appropriate oversight of contract manufacturers and suppliers.

Compliance with applicable import and manufacturing authorisation requirements.

The TGA regulates relevant manufacturing activities and provides guidance on applicable standards. Requirements vary according to the product, manufacturing activity and relevant exemptions.

Department of Finance+2

Legal consequence: A medicine's marketing authorisation does not excuse non-compliance with manufacturing requirements. Regulatory action may be available where a sponsor or manufacturer fails to comply with the applicable law or authorisation conditions.

6. Post-market surveillance and pharmacovigilance

Regulation continues after a biopharmaceutical is authorised. Approval is not a permanent guarantee that the product can be supplied without further oversight.

Sponsors may have continuing obligations relating to:

Reporting adverse events and complying with applicable safety-reporting requirements.

Investigating safety signals and quality defects.

Updating product information when new evidence emerges.

Maintaining appropriate manufacturing and distribution controls.

Conducting recalls or other corrective actions when required.

Complying with ARTG conditions and directions issued under the legislation.

For biological medicines, pharmacovigilance is particularly significant because immunogenicity, contamination, manufacturing changes and other product-specific risks may emerge through broader clinical use.

For statutory biologicals, Part 3-2A of the Therapeutic Goods Act 1989 provides mechanisms for imposing conditions, suspending or cancelling ARTG entries, obtaining information and requiring public notification or recalls in the circumstances specified by law.

Federal Register of Legislation+1

Regulatory enforcement

Depending on the applicable provisions and circumstances, regulatory responses can include:

Requests or statutory demands for information.

Conditions on an authorisation or ARTG entry.

Suspension or cancellation.

Product recalls and safety communications.

Civil penalties or criminal prosecution for relevant contraventions.

A company may face more than one type of legal exposure—for example, regulatory enforcement for unlawful supply and separate civil litigation involving an alleged injury or defective product.

7. Biosimilars and competition law

A biosimilar is a biological medicine demonstrated to be highly similar to a reference biological medicine, with no clinically meaningful differences in safety, efficacy and quality established under the applicable scientific and regulatory framework.

Unlike a conventional generic medicine, a biosimilar cannot necessarily be evaluated simply by showing that it contains the same active ingredient. Biological molecules can be structurally complex, and manufacturing processes may influence their characteristics.

Australian regulation therefore requires an appropriate scientific comparison with the reference product. The precise evidence depends on the product and the applicable TGA requirements.

Legal significance

Biosimilar regulation involves a balance between:

Patient safety and confidence in treatment.

Competition and affordability.

Protection of legitimate patent rights.

Prevention of misleading claims about similarity or interchangeability.

Appropriate prescribing and substitution practices.

Regulatory approval does not itself resolve patent infringement. A biosimilar might meet the relevant TGA requirements while a separate patent dispute concerns its manufacture, formulation, use or proposed launch date.

Likewise, the expiry of a patent does not automatically grant marketing authorisation: the biosimilar must still satisfy the relevant regulatory requirements.

8. Advertising, labelling and promotion

Biopharmaceutical sponsors must ensure that advertising and promotional material comply with the Therapeutic Goods Act 1989, the applicable advertising code and other relevant requirements.

The statutory framework addresses false or misleading representations, prohibited claims and non-compliant advertising. Depending on the circumstances, contraventions may result in civil penalties or criminal liability.

Federal Register of Legislation+1

Important compliance issues include:

Promoting a product only for authorised indications, subject to the applicable legal rules.

Avoiding unsupported efficacy and safety claims.

Ensuring that product information and risk statements are appropriate.

Avoiding misleading comparisons between a reference biologic and a biosimilar.

Complying with restrictions on advertising prescription medicines to the public.

For products regulated as biologicals, the Act contains specific provisions addressing false or misleading representations about regulatory status and advertising outside accepted indications.

Federal Register of Legislation+1

9. Special access and unapproved biopharmaceuticals

Australia permits certain pathways for access to therapeutic goods that have not been included in the ARTG. These pathways are subject to their own eligibility criteria, conditions and safeguards.

Relevant routes may include:

Clinical trials: Use of unapproved goods for experimental purposes under the applicable CTN or CTA scheme.

Special Access Scheme (SAS): Access to specified unapproved therapeutic goods for individual patients in eligible circumstances.

Authorised Prescriber pathway: Authorisation for eligible practitioners to prescribe certain unapproved therapeutic goods to specified classes of patients.

The legal requirements vary by pathway, product and patient circumstances. Special access should not be treated as equivalent to general marketing authorisation.

The TGA's guidance confirms that the CTN and CTA schemes are distinct; the CTA scheme involves a TGA assessment, while the CTN scheme follows a notification model with ethics review. Certain Class 4 biologicals are subject to mandatory CTA requirements, subject to specified exceptions.

Therapeutic Goods Administration (TGA)+2

10. Intellectual property and pharmaceutical patents

Biopharmaceutical regulation operates alongside Australia's patent system under the Patents Act 1990 (Cth).

Patents may concern:

The active biological substance.

A manufacturing or purification process.

A formulation or delivery system.

A therapeutic use.

Certain inventions involving recombinant technology or biological processes.

Patent protection and regulatory approval serve different functions. A patent confers legally defined exclusionary rights; TGA authorisation determines whether the relevant product may be supplied under therapeutic-goods legislation.

A dispute over patent validity, infringement or extension of patent term can affect when a competing product enters the market, even where the regulatory process has been completed.

11. Important Australian case laws

Australian courts have addressed pharmaceutical patents, therapeutic-goods classification, regulatory decision-making and public reimbursement. The following decisions are relevant to biopharmaceutical regulation, although not all directly determine TGA approval standards.

Case 1: Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd [2013] HCA 50

High Court of Australia · 4 December 2013

Facts and legal issue: The dispute concerned a patent claiming a method of administering a pharmaceutical substance to prevent or treat a medical condition. The Court considered whether methods of medical treatment could constitute patentable inventions and the scope of infringement provisions relating to pharmaceutical uses.

Decision and principle: The High Court recognised that a method of medical treatment of the human body can constitute a patentable invention under the Patents Act 1990 (Cth). The decision also considered infringement in the context of supplying a substance for a patented therapeutic use.

High Court of Australia+1

Relevance to biopharmaceuticals: A new therapeutic application of an existing biological substance may raise patentability and infringement questions. The case illustrates that regulatory approval and patent rights are separate legal questions.

Case 2: Commonwealth of Australia v Sanofi [2024] HCA 47

High Court of Australia · 11 December 2024

Facts: The dispute arose from pharmaceutical patent litigation involving clopidogrel. An interlocutory injunction restrained the entry of a generic product, and the Commonwealth sought compensation for losses associated with additional Pharmaceutical Benefits Scheme expenditure.

Legal issue: The Court considered how loss should be established under an undertaking as to damages, including the counterfactual question of what would probably have happened if the injunction had not been granted.

Principle: The judgment addressed the evidentiary burden and assessment of loss in litigation involving pharmaceutical market entry and public reimbursement.

High Court of Australia+1

Relevance: Where patent litigation delays the entry of a competing biological medicine, the economic consequences may extend beyond the manufacturers to public reimbursement expenditure. The case is relevant to those consequences, rather than to the scientific criteria for TGA approval.

Case 3: H. Lundbeck A/S v Sandoz Pty Ltd [2022] HCA 4

High Court of Australia · 9 March 2022

Facts: The dispute concerned a settlement agreement granting a non-exclusive patent licence and whether that licence extended to acts occurring during a subsequently extended patent term.

Legal issue: The Court considered the construction of the settlement agreement in the context of the statutory provisions governing pharmaceutical patent extensions and infringement proceedings.

Relevance: Biopharmaceutical market-entry planning can be affected by patent extensions, licensing arrangements and the interpretation of commercial agreements. Regulatory authorisation alone does not resolve these issues.

High Court of Australia+1

Case 4: Comptroller-General of Customs v Pharm-A-Care Laboratories Pty Ltd [2020] HCA 2

High Court of Australia · 5 February 2020

Facts: The case concerned the customs tariff classification of vitamin and garcinia preparations. The Court examined whether the products fell within the relevant category of medicaments or another tariff classification.

Principle: The judgment addressed statutory interpretation and the classification of therapeutic or prophylactic products for customs purposes.

High Court of Australia

Relevance: Classification can have consequences across multiple legal regimes, including customs, importation and therapeutic-goods regulation. However, a tariff classification decision is not a substitute for determining whether a product satisfies the TGA's statutory definition of a medicine or biological.

Case 5: Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd [2025] FCAFC 161

Full Court of the Federal Court of Australia · 1 December 2025

Facts: The litigation concerned an extension of patent term for a controlled-release injectable aripiprazole formulation.

Legal issue: The dispute involved the meaning of “pharmaceutical substance” for the purposes of the patent-term-extension provisions and whether the relevant formulation supported the extension.

Principle: The Full Court addressed the distinction between the pharmaceutical substance and a formulation containing that substance. The High Court subsequently granted special leave to appeal in March 2026, so the Full Court decision should not be described as the final High Court determination of the dispute.

IPA Manuals+2

Relevance: This distinction can be important for complex injectable biologics and other medicines where the active substance, delivery formulation and manufacturing technology may be protected by different patent claims.

Case 6: Parry v Secretary, Department of Health [2023] HCA 9

High Court of Australia · 16 March 2023

Legal issue: The decision concerned the High Court's jurisdiction and the remittal of proceedings raising issues under the Therapeutic Goods Act 1989 (Cth) to the Federal Court.

Principle and relevance: The case illustrates procedural questions about the appropriate forum for disputes arising under therapeutic-goods legislation. It was a procedural decision, not a substantive ruling establishing the safety or efficacy requirements for biopharmaceutical approval.

High Court of Australia

Comparative summary

Important qualification: These cases illuminate the legal environment surrounding pharmaceutical products, but they do not collectively constitute a direct body of precedent on every aspect of TGA biopharmaceutical authorisation. Product-specific statutory requirements and current TGA guidance remain essential.

12. Public funding and affordability

A biopharmaceutical may receive TGA approval but remain too expensive for many patients without public subsidy.

The Pharmaceutical Benefits Scheme is a separate mechanism for subsidising eligible medicines. The PBAC evaluates medicines for possible PBS listing, including relevant considerations concerning comparative clinical benefit and cost-effectiveness.

This produces two distinct regulatory questions:

Does the medicine meet the applicable requirements for market authorisation?

Should the medicine be subsidised using public funds, and on what terms?

The distinction is legally and economically important because a medicine can be authorised for supply without being listed on the PBS.

Health, Disability & Ageing Dept.+1

13. Constitutional and administrative law considerations

Australian biopharmaceutical regulation is also subject to broader public-law principles.

Administrative legality: Regulatory decisions must be made within the powers conferred by legislation and in accordance with applicable procedural requirements.

Procedural fairness: Where the law requires a fair process, an affected applicant or sponsor may be entitled to an appropriate opportunity to respond before certain adverse decisions are made.

Judicial review: A legally reviewable decision may be challenged on recognised grounds, such as jurisdictional error or failure to comply with mandatory legal requirements. Judicial review does not ordinarily permit a court simply to substitute its own scientific assessment for that of the regulator.

Privacy and confidentiality: Clinical-trial information, patient data and commercially sensitive manufacturing information may be subject to applicable privacy, confidentiality and disclosure rules.

Research ethics: Human-subject research must comply with applicable ethical and legal requirements, including appropriate consent and independent ethical oversight.

These principles operate alongside the product-specific rules in the Therapeutic Goods Act 1989 and related instruments; they do not create a general exemption from those requirements.

14. Practical example: An Australian company developing a monoclonal antibody

Consider a hypothetical Australian company developing a monoclonal antibody for an autoimmune disease.

Stage 1 — Classification and development

The company establishes the medicine's regulatory classification and develops an appropriate preclinical and clinical evidence package.

Stage 2 — Clinical trials

It obtains the necessary ethics approvals and complies with the applicable CTN or CTA requirements.

Stage 3 — Marketing application

The sponsor submits evidence concerning manufacturing quality, safety, efficacy, product information and other applicable requirements to the TGA.

Stage 4 — Market access

If the application is approved, the company complies with ARTG conditions, relevant supply requirements and any applicable prescribing restrictions. PBS listing is a separate decision.

Stage 5 — Continuing compliance

The company monitors safety, maintains quality systems, reports relevant problems and responds to regulatory directions or recall requirements when applicable.

If a competing company develops a biosimilar, the competitor must independently satisfy the relevant regulatory requirements and assess potential patent issues. The first company's approval does not automatically prevent the competing product from being approved, but patent rights may affect lawful commercial launch.

15. Critical assessment of the Australian framework

Strengths

A centralised national regulator supports consistent standards for medicines.

Risk-based regulation allows different requirements for different product categories.

Clinical-trial and post-market systems support continuing safety oversight.

Separate patent and reimbursement systems make it possible to address intellectual property and affordability through distinct legal mechanisms.

Special access pathways can facilitate treatment with certain unapproved products in eligible circumstances.

Challenges

Complex biological manufacturing can make comparability assessments difficult.

Clinical development may be expensive and time-consuming.

Patent disputes can delay competition even after regulatory requirements are met.

High prices can limit access to advanced therapies.

Scientific uncertainty may persist after approval, requiring continuing surveillance.

Classification disputes and changing technology can complicate regulatory planning.

The central policy challenge is to protect patients without unnecessarily delaying beneficial innovation or preventing appropriate competition.

16. Conclusion

Biopharmaceutical regulation in Australia is a multi-layered legal system combining market authorisation, scientific assessment, manufacturing controls, clinical-trial oversight, post-market surveillance, advertising restrictions, patent law and public reimbursement.

The Therapeutic Goods Act 1989 (Cth) and the TGA's regulatory framework are central, but classification is critical: biological medicines and statutory biologicals do not necessarily follow the same pathway.

The case law demonstrates that pharmaceutical regulation cannot be understood in isolation. Patentability, patent extensions, licensing, damages, customs classification and judicial review can all affect the development and commercial availability of biopharmaceuticals. Nevertheless, the decisive question for market authorisation remains whether the product satisfies the applicable statutory and scientific requirements.

Primary sources for further study

Therapeutic Goods Act 1989 — Federal Register of Legislation

TGA — Biological medicines

TGA — Australian Regulatory Guidelines for Biologicals

TGA — Clinical trials

High Court of Australia — Judgments

This explanation is for academic and general informational purposes. For an actual product submission, the current legislation, product classification, applicable standards and TGA guidance should be checked against the specific medicine and proposed use.